Oncology Corporate Profile
Sanofi engages in the research, development, manufacture, and marketing of healthcare products worldwide. It offers products in various therapeutic fields, including cardiovascular, thrombosis, oncology, metabolic disorders, central nervous system, and internal medicine and vaccines.
|Campath«•||alemtuzumab||Campath is a CD52-directed cytolytic antibody indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia.|
|Clolar«•||clofarabine||Clolar«• is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. This use is based on the induction of complete responses. Randomized trials demonstrating increased survival or other clinical benefit have not been conducted.|
|Elitek«•||rasburicase||ELITEK is indicated for the initial management of plasma uric acid levels in pediatric patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.|
|Eloxatin«•||oxaliplatin||ELOXATIN, used in combination with infusional 5-FU/LV, is indicated for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor. The indication is based on an improvement in disease-free survival, with no demonstrated benefit in overall survival after a median follow up of 4 years.|
ELOXATIN, used in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum.
|Jevtana«•||cabazitaxel||JEVTANA is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel containing treatment regimen.|
|Taxotere«•||docetaxel||Taxotere is a microtubule inhibitor used for:|
Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC
Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC
Hormone Refractory Prostate Cancer (HRPC): with prednisone in androgen independent (hormone refractory) metastatic prostate cancer
Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction
Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN.
|Thyrogen«•||thyrotropin alfa||Thyrogen (thyrotropin alfa for injection) is indicated for use as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer. Thyrogen (thyrotropin alfa for injection) is indicated for use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a neartotal|
or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of metastatic thyroid cancer.
|Zaltrap«•||aflibercept||ZALTRAP, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen.|
View additional information on commercial products here »
|Brand / Product||Class||Area of Study||Phase||Partnership|
|larotaxel / XRP9881||taxane (semi-synthetic)||Bladder cancer||III|
|alvocidib / HMR1275||cyclin-dependent kinase inhibitor||Chronic Lymphocytic Leukemia (CLL)||III|
|S-1||fluoropyrimidine (oral)||Colorectal cancer||III|
|S-1||fluoropyrimidine (oral)||Gastric cancer||III|
|SAR302503 (TG101348)||JAK2 inhibitor||Myelofibrosis||III|
|xaliproden / SR57746||neurotrophic||Peripheral sensory neuropathies||III|
|isatuximab||Anti-CD38 naked mAb||Relapsed refractory multiple myeloma||III|
|ombrabulin / AVE8062||vascular disrupting agent||Sarcoma||III|
|Campath_ / alemtuzumab||anti-CD52 monoclonal antibody||2nd line metastatic Chronic Lymphocytic Leukemia (CLL)||III|
|Clolarp_ / clofarabine||antimetabolite||Acute Myelogenous Leukemia (AML)||III|
|Jevtana / cabazitaxel / XRP6258||taxane||1st line metastatic hormone-refractory Prostate cancer (HRPC)||III|
|Taxoterep / docetaxel||taxane||Pediatric cancer||III|
|Zaltrap / aflibercept / VEGF Trap||VEGF-A inhibitor||1st line metastatic hormone-refractory Prostate cancer (HRPC)||III||Regeneron|
|Zaltrap / aflibercept / VEGF Trap||VEGF-A inhibitor||2nd line metastatic Non Small Cell Lung Cancer (NSCLC)||III||Regeneron|
|larotaxel / XRP9881||taxane||1st line metastatic Breast cancer||II|
|larotaxel / XRP9881||taxane||Adjuvant Breast cancer||II|
|SAR439684||PD-1 inhibitor||Advanced cutaneous squamous cell carcinoma (CSCC)||II|
|SAR3419||anti-CD19 monoclonal antibody (maytansin-loaded)||B-cell Acute Lymphocytic Leukemia (B-ALL)||II||Immunogen|
|tasidotin||analog of dolastatin 15||Melanoma||II||Ergomed Group|
|thymoglobulin||immunosuppressive||Myelodysplastic Syndrome (MDS)||II|
|Clolar / clofarabine||antimetabolite||Myelodysplastic Syndrome (MDS)||II|
|Zaltrap / aflibercept / VEGF Trap||VEGF-A inhibitor||1st line metastatic Colorectal cancer||II||Regeneron|
|SAR103168||multiple tyrosine kinase inhibitor||Acute Myelogenous Leukemia (AML)||I|
|AVE9633||anti-CD33 monoclonal antibody (maytansin-loaded)||Acute Myelogenous Leukemia (AML)||I|
|XL765||PI3K and mTOR inhibitor||Glioblastoma Multiforme (GBM)||I||Exelixis|
|SAR650984||anti-CD38 monoclonal antibody (naked)||Various cancer types||I||Immunogen|
|SSR97225||antimitotic agent||Various cancer types||I|
|SSR244738||antitumoral agent||Various cancer types||I|
|SAR428926||anti-Lamp1 monoclonal antibody (maytansin-loaded)||Various cancer types||I|
|SAR408701||anti-CEACAM5 monoclonal antibody (maytansin-loaded)||Various cancer types||I|
|SAR566658||anti-DS6 monoclonal antibody (maytansin-loaded)||Various cancer types||I|
|Mozobil_ / plerixafor||immunostimulant||Acute Myelogenous Leukemia (AML)||I|
|Gene Signature Test||diagnostics||Colorectal cancer genomic analysis||Development|
|Multiplex Predictive||diagnostics||Various cancer types||Development|
View additional information on product candidates here »
10/31/2016 10:41 am
(PharmaTimes [UK]) Oct 31, 2016 - US regulators are refusing to approve Sanofi and Regeneron's sarilumab to treat patients with rheumatoid arthritis until certain manufacturing issues are addressed.
9/27/2016 11:55 am
(Business Insider/Reuters) Sept 26, 2016 - Sanofi SA said on Monday the U.S. Department of Health and Human Services approved $43.18 million in funding to accelerate the development of a Zika vaccine, as part of efforts to prevent the infection.
9/26/2016 11:31 am
(Boston Business Journal) Sept 26, 2016 - The second of two potential drugs for immune system disorders that are together expected to bring in peak annual revenues of between $3 billion and $7 billion to Sanofi Genzyme and a New York based partner in the next few years is expected to have a decision on U.S. approval by next spring.
9/23/2016 11:26 am
(Reuters) Sept 22, 2016 - UnitedHealth Group (UNH.N), the largest U.S. health insurer, will stop covering several brand-name drugs as of next year, reinforcing a trend of payers steering prescriptions to lower-priced options.
9/12/2016 12:09 pm
(Bloomberg Technology) Sept 12, 2016 - French drugmaker Sanofi and Alphabet Inc.'s life sciences arm plan to invest about $500 million in a joint venture to tackle diabetes amid forecasts for the number of people with the disease to surge.
8/22/2016 06:53 am
(Bloomberg) Aug 22, 2016 - Pfizer Inc. agreed to buy Medivation Inc. in a deal that values the company at about $14 billion and leaves French drugmaker Sanofi jilted.
8/17/2016 11:26 am
(Bloomberg) Aug 16, 2016 - Amgen Inc., Sanofi and Regeneron Pharmaceuticals Inc. would need to cut prices on their new cholesterol-lowering drugs by more than two-thirds to make them cost-effective to use in the U.S., a study found.
8/4/2016 11:19 am
(Reuters) Aug 4, 2016 - French drugmaker Sanofi secured EU antitrust approval on Thursday for its proposed buy of German peer Boehringer Ingelheim's consumer health business after agreeing to divest businesses from both companies in nine EU countries.
7/12/2016 10:27 am
(Bloomberg) July 12, 2016 - Sanofi is going west once more in its search for cancer gold. Chief Scientific Officer Gary Nabel says to revive its oncology business, Sanofi is hunting for assets ranging from approved cancer drugs to experimental ones that mine new expertise, such as exploiting flaws in tumor cells.
7/6/2016 12:22 pm
(NASDAQ/Dow Jones Business News) July 6, 2016 - Sanofi SA has formed a partnership with the U.S. Army to expand research and development of an experimental Zika vaccine that has shown promise in early laboratory studies and is among a few candidates expected to be tested on humans in the coming months.
7/6/2016 12:05 pm
(Reuters) July 5, 2016 - U.S. cancer drug company Medivation Inc said on Tuesday it had agreed to provide confidential information to French pharmaceutical company Sanofi SA as part of exploring a sale that would be open to other bidders.
6/23/2016 11:33 am
(Bloomberg) June 22, 2016 - Sanofi, the French drugmaker, is considering improving its $9.3 billion takeover offer for Medivation Inc. by committing to making future payments if the U.S. biotech company meets certain targets, according to people familiar with the matter.
6/20/2016 12:05 pm
(STAT) June 20, 2016 - The Supreme Court dealt a defeat to the pharmaceutical industry Monday in a closely watched patent law case that drug makers had argued endangered their continued investments in drug research and development.
6/9/2016 11:32 am
(Reuters) June 8, 2016 - Sanofi said on Wednesday it aims to remove the board of takeover target Medivation by Aug. 1 at the latest.
6/2/2016 11:58 am
(TheStreet.com) June 2, 2016 - The cancer drug maker moves to lock new shareholders out of an upcoming vote.
5/26/2016 12:02 pm
(Bloomberg) May 25, 2016 - Sanofi’s once-a-day shot for diabetes that combines two drugs should be approved for sale, a group of advisers to the U.S. Food and Drug Administration said.
5/26/2016 11:04 am
(QIAGEN) May 25, 2016 – An initial project will be to develop and market PITX2 as a marker to predict effectiveness of anthracycline treatment in triple negative and other high-risk breast cancer patients.
5/25/2016 11:15 am
(Reuters) May 25, 2016 - French drugmaker Sanofi named eight candidates to replace the entire board of Medivation on Wednesday, stepping up pressure on the U.S. cancer drug company which has rejected its $9.3 billion takeover approach.
5/25/2016 11:01 am
(ABC News/Associated Press) May 24, 2016 - Vice President Joe Biden will bring together scientists, oncologists, donors and patients for a national conference on cancer research in Washington, the White House said Tuesday.
5/24/2016 11:01 am
(4-traders) May 24, 2016 - Celsion Corporation, an oncology drug development company, today provided an update on its ongoing OVATION study, a Phase Ib dose escalating clinical trial combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with advanced ovarian cancer who will undergo neoadjuvant chemotherapy followed by interval debulking surgery.
5/23/2016 12:13 pm
(Reuters) May 23, 2016 - A preliminary review by the U.S. Food and Drug Administration questioned the usefulness of a combination diabetes drug made by Sanofi SA's and said it was unclear whether one component, lixisenatide, contributed to its benefit.
5/20/2016 11:03 am
(Medscape Medical News) May 20, 2016 - A Louisiana-based biopharmaceutical company is betting that its experimental immunotherapeutic vaccine can keep previously untreated prostate cancer in check.
5/13/2016 11:51 am
(Reuters) May 13, 2016 - France's Sanofi SA was moving ahead on Friday with preparations to replace Medivation Inc's board of directors after the U.S. cancer drug maker refused to engage with it in sale talks based on a $9.3 billion acquisition offer.
5/13/2016 11:04 am
(NASDAQ) May 12, 2016 - HTG Molecular Diagnostics, Inc., a provider of instruments and reagents for molecular profiling applications, today announced a research collaboration agreement with Bristol-Myers Squibb to evaluate the potential for immuno-oncology molecular profiling in multiple tumor types.
5/12/2016 12:31 pm
(Reuters) May 11, 2016 - Drug regulation has failed to keep up with a globalized world and governments should harmonize oversight to improve patients' access to new and innovative medicines.
5/6/2016 12:12 pm
(Reuters) May 5, 2016 - Two rival cholesterol-lowering injections from Sanofi and Amgen have been recommended by Britain's healthcare cost watchdog after the manufacturers offered special discounts to the country's state-run health service.
5/6/2016 11:36 am
(Reuters) May 5, 2016 - France's Sanofi said it could raise its proposed $9.3 billion deal to buy Medivation if the U.S. cancer drugmaker engaged in talks, threatening to go directly to shareholders to oust the board if not.
5/6/2016 06:59 am
(Wall Street Journal) May 5, 2016 - Sanofi SA on Thursday said it sent a letter to Medivation Inc. saying it would try to remove and replace members of the U.S. biotech firm’s board if it didn't engage in takeover talks.
5/5/2016 12:17 pm
(Medivation) May 5, 2016 - Medivation, Inc. today reiterated its rejection of Sanofi's substantially inadequate proposal to acquire the Company for $52.50 per share in cash, following the receipt of a letter from Sanofi.
5/4/2016 11:45 am
(Reuters) May 4, 2016 - Sanofi sees a strong strategic fit with U.S. cancer drug maker Medivation, the French pharmaceuticals company's chief executive said on Wednesday after recently approaching the company about a tie-up.
4/29/2016 11:17 am
(New York Times/DealBook) Apr 29, 2016 - Medivation, which makes drugs for prostate cancer, has a message for the French drug company Sanofi: The $9.3 billion cash takeover offer was not good enough.
4/27/2016 11:04 am
(Penn Medicine) Apr 26, 2016 - Long-term use of the cholesterol-lowering drugs known as statins does not appear to decrease a patient's risk of colorectal cancer, suggests a new, large case-control study from Penn Medicine researchers published this week in PLOS Medicine.
4/18/2016 11:03 am
(Morningstar) Apr 18, 2016 - Fourth Designation for KEYTRUDA follows breakthrough status in advanced melanoma, non-small cell lung cancer, and colorectal cancer.
4/7/2016 11:05 am
(NEJM) Apr 7, 2016 - "Moving from volume to value" is health care reform's latest mantra. Policymakers hope to replace fee-for-service systems with value-based approaches that reward improved outcomes achieved at lower cost. Ground zero in these efforts is the Medicare Physician Fee Schedule (MPFS).
3/28/2016 07:03 am
(Wall Street Journal) Mar 24, 2016 - Medicare officials said they have temporarily abandoned a proposed measure that would have penalized doctors for ordering “non-recommended” prostate-specific antigen tests to screen for prostate cancer, citing a wave of negative comments.
3/21/2016 11:02 am
(Healio) Mar 18, 2016 - Longer surgical interval following initial biopsy may worsen RFS outcomes in patients with residual melanoma, according to a retrospective review presented at HemOnc Today Melanoma and Cutaneous Malignancies.
3/18/2016 10:00 am
(LiveScience) Mar 17, 2016 - Marijuana could potentially help cancer patients who have nausea or pain, and could possibly even be used as a treatment for certain cancers, but much more research is needed before any of these uses could be recommended, a new review article said.
3/9/2016 12:03 pm
(Boston Business Journal/BioFlash blog) Mar 9, 2016 - Investors are taking a wait-and-see approach this morning after Cambridge biotech Epizyme laid out a grand vision to get its lead cancer drug approved, in the best case scenario, in a little over two years.
2/25/2016 07:00 am
(Reuters) Feb 25, 2016 - AstraZeneca's bold move to buy 55 percent of privately held biotech firm Acerta Pharma for $4 billion in December has been vindicated, at least in part, by the award of special "orphan" status to the key experimental drug involved.
1/27/2016 12:05 pm
(STAT) Jan 26, 2016 - Donald Trump stunned the health care world Monday night with his call for Medicare to negotiate drug prices — an idea that’s straight out of Hillary Clinton’s and Bernie Sanders playbooks, and one that other Republicans won’t touch.
1/26/2016 11:02 am
(Gizmodo) Jan 26, 2016 - The process of identifying cancer—from taking a sample of a tumor to getting the results back from a laboratory—can be long-winded. When there isn’t time for all that, this new hand-held microscope could help doctors identify cancer cells in just a few moments.
1/25/2016 11:04 am
(Reuters) Jan 25, 2016 - The mosquito-borne Zika virus, which has been linked to brain damage in thousands of babies in Brazil, is likely to spread to all countries in the Americas except for Canada and Chile, the World Health Organization said on Monday.
1/20/2016 12:01 pm
(Forbes) Jan 20, 2016 - While their drug has shown no adverse reactions in Phase 1 studies or ongoing Phase 2 trials to date, Janssen discontinues FAAH inhibitor dosing in two trials until more is known about the Bial drug trial tragedy in Rennes, France.
8/11/2015 11:04 am
(MedPage Today/The Gupta Guide) Aug 10, 2015 - Ibrutinib (Imbruvica), an oral inhibitor of Bruton tyrosine kinase, produced rapid and durable responses in heavily treated patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) -- now followed for a median of 26.7 months -- according to an updated report of the safety and efficacy of an open-label phase II registration trial.
8/10/2015 11:04 am
(CHLA) Aug 7, 2015 - Medulloblastoma, the most commonly occurring malignant brain tumor in children, can be classified into four subgroups—each with a different risk profile requiring subgroup-specific therapy.
8/6/2015 11:01 am
(MSKCC/On Cancer blog) Aug 6, 2015 - Memorial Sloan Kettering scientists have discovered how new analgesic medications work without the downsides of traditional opioid painkillers.
7/28/2015 12:00 pm
(Bayer) July 28, 2015 – Bayer HealthCare and the Swedish company Sprint Bioscience AB have entered into a collaboration and license agreement for the research, development, and commercialization of oncological drug candidates.
7/27/2015 12:01 pm
(Reuters) July 24, 2015 - The U.S. Food and Drug Administration on Friday approved two treatments for less common forms of hepatitis C virus (HCV) infections.
7/27/2015 12:00 pm
(Reuters Health) July 27, 2015 - Companies fail to report roughly one in 10 serious and unexpected medication side effects to the U.S. Food and Drug Administration (FDA) within a 15-day window specified by federal regulations to protect patient safety, a study finds.
7/27/2015 11:05 am
(CNN Money) July 27, 2015 - Horizon Pharma plc today announced a collaboration with Fox Chase Cancer Center to study ACTIMMUNE (interferon gamma-1b) in combination with PD-1/PD-L1 inhibitors in various forms of cancer including advanced urothelial carcinoma (bladder cancer) and renal cell carcinoma.